journal article·2022-11-23

Enhanced Sensitivity of Tumor Cells to Autophagy Inhibitors Using Fasting-Mimicking Diet and Targeted Lysosomal Delivery Nanoplatform

Ruihao Qian, Guoliang Cao, Wen Su, Jie Zhang, Yue Jiang, Haohao Song, Fuhao Jia, Hai Wang

Nano Letters· Volume 22· Issue 22
Publisher page

Abstract

Autophagy is one of the key pathways for tumor cell survival and proliferation. Therefore, inhibition of autophagy has been extensively studied for cancer therapy. However, current autophagy inhibitors lack specificity and are ineffective in limiting tumor progression. Herein, we report a nanoplatform for tumor-site-targeted delivery of hydroxychloroquine (HCQ) using insulin-like growth factors 2 receptor (IGF2R)-targeted liposomes (iLipo-H). A fasting-mimicking diet (FMD) is used to increase the autophagy levels in tumor cells, thereby increasing the sensitivity of tumor cells to HCQ. In addition, FMD treatment upregulates the expression of IGF2R in tumor cells, but not normal cells. Consequently, iLipo-H nanoparticles efficiently accumulate at the tumor site under FMD condition. In vivo studies demonstrate that iLipo-H nanoparticles efficiently inhibit 4T1 tumor growth without obvious side effects, especially under FMD condition. This study provides a promising strategy to increase the sensitivity of tumor cells to autophagy inhibitors for effective cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Histone Deacetylase Inhibitors Research · Sirtuins and Resveratrol in Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China

University of Chinese Academy of Sciences, Beijing 100049, China

State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin 150040, China

Funding

National Key R&D Program of China · The Strategic Priority Research Program of Chinese Academy of Sciences · Foundation of National Center for Nanoscience and Technology

References (32)

Show source-provided references
1. 10.1038/ncb0910-81410.1038/ncb0910-814 ↗
2. 10.4161/23723556.2014.98591310.4161/23723556.2014.985913 ↗
3. 10.1038/s41574-021-00551-910.1038/s41574-021-00551-9 ↗
4. 10.1038/nrc326210.1038/nrc3262 ↗
5. 10.1038/s41568-018-0030-710.1038/s41568-018-0030-7 ↗
6. 10.1016/j.molcel.2020.05.03410.1016/j.molcel.2020.05.034 ↗
7. 10.1038/s41467-020-17882-210.1038/s41467-020-17882-2 ↗
8. 10.1007/s00018-015-2104-y10.1007/s00018-015-2104-y ↗
9. 10.1016/j.phrs.2016.01.02810.1016/j.phrs.2016.01.028 ↗
10. 10.1038/s41580-019-0120-810.1038/s41580-019-0120-8 ↗
11. 10.1021/acs.biomac.7b0002310.1021/acs.biomac.7b00023 ↗
12. 10.1101/gad.159920710.1101/gad.1599207 ↗
13. 10.1073/pnas.070810010510.1073/pnas.0708100105 ↗
14. 10.1021/acs.nanolett.2c0035610.1021/acs.nanolett.2c00356 ↗
15. 10.1002/advs.20220048210.1002/advs.202200482 ↗
16. 10.1016/j.clnu.2017.06.01710.1016/j.clnu.2017.06.017 ↗
17. 10.1038/s41568-018-0048-x10.1038/s41568-018-0048-x ↗
18. 10.1021/acs.molpharmaceut.5b0017710.1021/acs.molpharmaceut.5b00177 ↗
19. 10.4161/auto.2348510.4161/auto.23485 ↗
20. 10.1002/advs.20190284710.1002/advs.201902847 ↗
21. 10.1021/nl501839q10.1021/nl501839q ↗
22. 10.1038/s41556-018-0201-510.1038/s41556-018-0201-5 ↗
23. 10.1074/jbc.M70282420010.1074/jbc.M702824200 ↗
24. 10.1080/15548627.2016.116293010.1080/15548627.2016.1162930 ↗
25. 10.1128/MCB.25.3.1025-1040.200510.1128/MCB.25.3.1025-1040.2005 ↗
26. 10.1021/acs.nanolett.9b0396810.1021/acs.nanolett.9b03968 ↗
27. 10.1002/advs.20200292210.1002/advs.202002922 ↗
28. 10.1016/j.jmb.2019.10.02810.1016/j.jmb.2019.10.028 ↗
29. 10.1080/15548627.2016.119275110.1080/15548627.2016.1192751 ↗
30. 10.1016/j.drup.2012.01.00410.1016/j.drup.2012.01.004 ↗
31. 10.1038/s41586-020-2229-510.1038/s41586-020-2229-5 ↗
32. 10.1021/acs.nanolett.2c0047810.1021/acs.nanolett.2c00478 ↗